Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 4/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14648049 | 1.00 | L3MBTL1 (0.76) | L3MBTL1SMN1; SMN2POLBHTTALDH1A1 | |
| SCHEMBL18901976 | 0.90 | L3MBTL1 (0.61) | L3MBTL1SMN1; SMN2POLBHTTALDH1A1 | |
| SCHEMBL2449353 | 0.86 | L3MBTL1 (1.00) | L3MBTL1SMN1; SMN2POLBHTTALDH1A1 | |
| SCHEMBL13379352 | 0.85 | L3MBTL1 (0.56) | L3MBTL1SMN1; SMN2POLBHTTALDH1A1 | |
| SCHEMBL13379349 | 0.85 | L3MBTL1 (0.56) | L3MBTL1SMN1; SMN2POLBALDH1A1HPGD | |
| SCHEMBL5842543 | 0.81 | SMN1; SMN2 (0.55) | L3MBTL1SMN1; SMN2POLBHTTALDH1A1 | |
| SCHEMBL6613615 | 0.81 | L3MBTL1 (0.51) | L3MBTL1SMN1; SMN2POLBHPGDGAA | |
| SCHEMBL843091 | 0.79 | SMN1; SMN2 (0.77) | L3MBTL1SMN1; SMN2POLBHTTALDH1A1 | |
| SCHEMBL1263215 | 0.79 | SMN1; SMN2 (0.77) | L3MBTL1SMN1; SMN2POLBHTTALDH1A1 | |
| SCHEMBL5390794 | 0.79 | SMN1; SMN2 (0.77) | L3MBTL1SMN1; SMN2POLBHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735398-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-04 | — | — | US | disclosed |
| US-8362020-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| EP-2519506-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | disclosed |
| WO-2011082077-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-07 | — | — | WO | disclosed |
| US-7067549-B2 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2006-06-27 | — | — | US | disclosed |
| US-20050192292-A1 | Pyrrolidone carboxamides | ACTELION PHARMACEUTICALS AG (CH) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | L3MBTL1 2276/4885SMN1; SMN2 4709/4885POLB 2039/4885 |
| US-20130085147-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | L3MBTL1 2276/4885SMN1; SMN2 4709/4885POLB 2039/4885 |
| US-20050192292-A1 | Pyrrolidone carboxamides | NPY1R, NPY5R, NPY2R | L3MBTL1 3047/4885SMN1; SMN2 3678/4885POLB 4023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.